ECSP10010417A - ALDH-2 INHIBITORS IN ADDICTION TREATMENT - Google Patents

ALDH-2 INHIBITORS IN ADDICTION TREATMENT

Info

Publication number
ECSP10010417A
ECSP10010417A EC2010010417A ECSP10010417A ECSP10010417A EC SP10010417 A ECSP10010417 A EC SP10010417A EC 2010010417 A EC2010010417 A EC 2010010417A EC SP10010417 A ECSP10010417 A EC SP10010417A EC SP10010417 A ECSP10010417 A EC SP10010417A
Authority
EC
Ecuador
Prior art keywords
aldh
inhibitors
addiction treatment
addiction
formula
Prior art date
Application number
EC2010010417A
Other languages
Spanish (es)
Inventor
Jeff Zablocki
Matthew Abelman
Ivan Diamond
Mar A Pia Arolfo
Lina Yao
Peidong Fan
Elfatih Elzein
Rao Kalla
Thao Perry
Tetsuya Kobayashi
Xiaofen Li
Wing Ming Keung
Yaroslav Bilokin
Robert Jiang
Michael Organ
Zhan Jiang
Guoxin Tao
Original Assignee
Gilead Palo Alto Inc
Endowment For Res In Human Biology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc, Endowment For Res In Human Biology Inc filed Critical Gilead Palo Alto Inc
Publication of ECSP10010417A publication Critical patent/ECSP10010417A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Los revelados son nuevos derivados de isoflavona que tienen la estructura de la Formula I Formula ILos que son de utilidad como inhibidores ALDH-2 para el tratamiento a mamiferos bajo la dependencia a drogas de adiccion, por ejemplo adiccion a agentes productores de dopamina tales como cocaina, morfina, anfetaminas, nicotina, y alcohol.The disclosed ones are new isoflavone derivatives that have the structure of Formula I Formula IL which are useful as ALDH-2 inhibitors for the treatment of mammals under dependence on drug addiction, for example addiction to dopamine producing agents such as cocaine , morphine, amphetamines, nicotine, and alcohol.

EC2010010417A 2008-01-24 2010-08-23 ALDH-2 INHIBITORS IN ADDICTION TREATMENT ECSP10010417A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/051862 WO2009094028A1 (en) 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction

Publications (1)

Publication Number Publication Date
ECSP10010417A true ECSP10010417A (en) 2010-11-30

Family

ID=39731733

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010417A ECSP10010417A (en) 2008-01-24 2010-08-23 ALDH-2 INHIBITORS IN ADDICTION TREATMENT

Country Status (13)

Country Link
EP (1) EP2254878A1 (en)
JP (1) JP2011510072A (en)
KR (1) KR20100130589A (en)
CN (1) CN101925590A (en)
AU (1) AU2008348372A1 (en)
BR (1) BRPI0822129A2 (en)
CA (1) CA2712750A1 (en)
EC (1) ECSP10010417A (en)
IL (1) IL207127A0 (en)
MA (1) MA32095B1 (en)
MX (1) MX2010008111A (en)
WO (1) WO2009094028A1 (en)
ZA (1) ZA201004671B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (en) * 2011-02-18 2011-08-24 中国药科大学 Preparation method and applications of isoflavone type compounds with selective estrogen receptor modulating activity
TWI567061B (en) 2011-07-01 2017-01-21 吉李德科學股份有限公司 Compounds for the treatment of addiction
AR087700A1 (en) * 2011-08-30 2014-04-09 Gilead Sciences Inc ALDH-2 INHIBITORS IN ADDICTION TREATMENT
CA3077606A1 (en) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. Combination therapy for preventing addiction
CN108276374B (en) * 2018-03-29 2020-01-31 天津科技大学 Flavonoid aromatase inhibitor and preparation method and application thereof
CN110922394B (en) * 2019-11-21 2021-04-06 中国科学院宁波材料技术与工程研究所 Bio-based intrinsic flame-retardant epoxy resin precursor based on natural flavonoid compound and preparation method and application thereof
WO2023235753A2 (en) * 2022-05-31 2023-12-07 University Of Maryland, Baltimore Aldh2 inhibitors and methods of use thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (en) * 1970-05-27 1973-02-28
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP1077697B1 (en) * 1998-05-12 2006-07-19 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
KR20060011785A (en) * 2002-06-27 2006-02-03 디 인다우먼트 포 리써치 인 휴먼 바이올로지, 인크. Compounds useful for the inhibition of aldh
CA2571421A1 (en) * 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
PL377180A1 (en) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Application of isoflavones and their derivatives in Mucopolysacharidose treatment
AU2007278877A1 (en) * 2006-07-27 2008-01-31 Gilead Palo Alto, Inc. ALDH-2 inhibitors in the treatment of addiction
EP2231149A2 (en) * 2007-11-06 2010-09-29 CV Therapeutics Inc. Aldh-2 inhibitors in the treatment of psychiatric disorders

Also Published As

Publication number Publication date
WO2009094028A1 (en) 2009-07-30
KR20100130589A (en) 2010-12-13
ZA201004671B (en) 2011-03-30
IL207127A0 (en) 2010-12-30
MA32095B1 (en) 2011-02-01
BRPI0822129A2 (en) 2015-06-23
MX2010008111A (en) 2010-11-30
JP2011510072A (en) 2011-03-31
CN101925590A (en) 2010-12-22
AU2008348372A1 (en) 2009-07-30
CA2712750A1 (en) 2009-07-30
EP2254878A1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
ECSP10010417A (en) ALDH-2 INHIBITORS IN ADDICTION TREATMENT
ECSP088919A (en) ALDH-2 INHIBITORS IN ADDICTION TREATMENT
ECSP13013087A (en) COMPOUNDS FOR ADDICTION TREATMENT
HN2012001413A (en) PIRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
CO6450612A2 (en) SUBSTITUTED 1-CYANOETHYLETHYCLIC CARBOXAMIDE 750 COMPOUNDS
UY35177A (en) NEWS DERIVED FROM BENCIMIDAZOL AS ANTAGONISTS OF EP4
UY30130A1 (en) DERIVATIVES OF TRICYCLE N-HETEROARIL-CARBOXAMIDS CONTAINING A BENCIMIDAZOL REST, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
CU20120013A7 (en) OXACINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CO6430459A2 (en) PROLIN DERIVATIVES AS CATEPSIN INHIBITORS
NI201000060A (en) TIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS INHIBITORS OF mTOR KINASE AND PI3 KINASE.
CR20110466A (en) ANTI-ERBB-3 / ANTI-C-MET ANTI-ERBB ANTIBODIES
UY31606A1 (en) DERIVATIVES OF AZABYCYCLIC CARBOXAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
CO7310531A2 (en) 4-methyl-2,3,8,9,9b-pentaaza-cyclopenta [a] naphthalenes
UY32432A (en) FUSIONED PYRIMIDINE COMPOUNDS AS AKT INHIBITORS
BR112012031508A2 (en) composition and use
UY35906A (en) NEWS DERIVED FROM BENCIMIDAZOL AS LIGANDOS OF EP4
CO6351779A2 (en) SMALL MOLECULA INHIBITORS OF THE ANDROGEN RECEPTOR N-TERMINAL ACTIVATION
ECSP11010992A (en) ANILINA-PYRIMIDINE DERIVATIVES SUBSTITUTED WITH SULFOXIMINE AS INHIBITORS OF CYCLINE-DEPENDENT KINASE (CDK), PRODUCTION AND USE OF THE SAME AS MEDICINAL PRODUCTS
UY31645A1 (en) NEW PHENYL-SUBSTITUTED IMIDAZOLIDINS, PROCEDURE FOR PREPARATION, MEDICATIONS THAT INCLUDE SUCH COMPOUNDS AND THEIR USE.
CO6650413A2 (en) Conjugator for prevention or treatment of nicotine addiction
UY32404A (en) 4-ARIL-BUTAN-1,3-DIAMIDS
CR11759A (en) NEW CLASS OF PIPERIDINES ESPIRO FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
HN2012001262A (en) NEW DERIVATIVES OF 8HETEROYCYCLE-CONDENSED PIPERIDINE) - (PIPERAZINIL) -1-ALCANONE OR (CONCENSED HETEROYCYCLE-PIRROLIDINE) - (PIPERAZINIL) -1-ALCANONE AND ITS USE AS P75 INHIBITORS
UY31646A1 (en) USE OF SUBSTITUTED PHENYLIMIDAZOLIDINS TO PRODUCE MEDICINES FOR THE TREATMENT OF METABOLIC SYNDROME
EA201490270A1 (en) ALDH-2 INHIBITORS FOR THE TREATMENT OF DEPENDENCE